Immune cell therapy takes on HPV
NCT ID NCT03351855
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether infusing HPV-specific immune cells (HPV-CTLs) can safely reduce or clear HPV infection in people who haven't responded to standard treatments. Up to 100 participants will receive 2 to 4 infusions of these cells. The study measures safety and viral load changes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HPV-specific immune cells (HPV-CTLs)
- What this could lead to
- If successful, this could offer a new treatment option for persistent HPV infections that don't respond to standard therapies.
- What could go wrong
- This is an early phase 1/2 trial with only 100 participants, so results may not apply broadly. Risks include immune reactions or lack of viral clearance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the HPV vaccine fully protect transgender women and people with HIV?
- Tweets that tell a story: a new approach to boosting HPV vaccination
- Could HPV shots start earlier? study tests vaccine in kids as young as 4
- ERs may soon offer At-Home HPV tests to reach women who skip screenings
- Could a common numbing drug help fight throat cancer?
- New program aims to protect HIV patients from HPV cancer